PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?

Authors

  • Robert O Bonow Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, USA
  • Ahmed M ElGuindy Department of Cardiology, Aswan Heart Centre, Egypt

Abstract

[first paragraph of article]

After several years of a disappointing series of negative clinical trials investigating novel therapies for systolic heart failure, the presentation of the landmark PARADIGM-HF [Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure] trial at the 2014 Congress of the European Society of Cardiology in Barcelona, with simultaneous publication in the New England Journal of Medicine,1has created considerable excitement and optimism. With knowledge that the trial had been halted prematurely by the independent data and safety monitoring committee (DSMB), the results were eagerly anticipated, and the trial results lived up to the expectations.

Downloads

Published

2017-06-30

Issue

Vol. 2014 No. 3 (2014)

Section

Lessons from the trials

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.